# DOAC in Patients with Child a or B Liver Cirrhosis

> **NCT05869591** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 40 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Apixaban 5 MG [Eliquis]
- **DRUG:** Edoxaban 60 MG [Lixiana]

## Key facts

- **NCT ID:** NCT05869591
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-18
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05869591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05869591, "DOAC in Patients with Child a or B Liver Cirrhosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05869591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*